Clearly, further studies are required, particularly in view of the emerging theme of TIMP-1 supporting tumour progression in lymphomas (Guedez et al, 1998; Kossakowska et al, 2000; Oelmann et al, 2002; Kuittinen et al, 2003; Liu et al, 2003), colorectal carcinoma (Holten-Andersen et al, 2005), carcinoma of the breast (Lee et al, 2003; Porter et al, 2004), and skin tumorigenesis (Rhee et al, 2004). Here, TIMP1 is linked to lymphoma.